Atlas Trials

Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer

Clinical trial NCT07298538 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07298538
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Unresectable Hepatocellular Carcinoma
Start date
2019-01-01
Primary completion
2025-12-01
Enrollment
800

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.